Dr. Qiang Zuo 左强
Chief Physician, Lecturer
Department of Medical Oncology, Nanfang Hospital, Southern Medical University, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of common malignant tumors, including chemotherapy, molecular targeted therapy, immunotherapy, minimally invasive diagnosis and treatment, cancer pain management, and emergency care. Specializes in thoracic and gastrointestinal tumors.
Dr. Zuo holds a medical doctorate and serves as a Chief Physician and Lecturer at Nanfang Hospital. Trained at the US National Institutes of Health (NIH), Dr. Zuo supervises doctoral students. Currently leads one National Natural Science Foundation project and three provincial projects. Has published 10 SCI papers as first or corresponding author.
Professional roles
- Member, Guangdong Branch of the Chinese Medical Association
- Standing Committee Member, Lung Cancer Professional Committee of Guangzhou Anti-Cancer Association
- Member, Oncology Branch of Guangdong Medical Doctor Association
- Member, Evidence-Based Medicine Branch of Guangdong Medical Association
Name order: in Chinese the family name comes first (Zuo Qiang). Papers usually list the name as Qiang Zuo or Zuo Q.
Selected publications
31 papers on PubMed matched by name and affiliation; 13 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Death Dis, 2026 (senior author): Endoplasmic reticulum stress-induced histone lactylation mediating immune escape of gastric cancer via PDIA6 overexpression in dendritic cells. PubMed 41896533
- Mol Cancer, 2026 (senior author): LncRNA NEAT1 promotes immunosuppression in gastric cancer under endoplasmic reticulum stress by maintaining the M(6)A methylation of SEMA3A in CAFs. PubMed 41782001
- Biochim Biophys Acta Mol Basis Dis, 2025 (senior author): Molecular mechanisms of transmitted endoplasmic reticulum stress mediating immune escape of gastric cancer via PVR overexpression in TAMs. PubMed 39486660
- Oncol Lett, 2023 (senior author): Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment. PubMed 37216167
- Clin Transl Oncol, 2023 (senior author): Molecular mechanism of XB130 adaptor protein mediates trastuzumab resistance in gastric cancer. PubMed 36284062
- J Exp Clin Cancer Res, 2023 (senior author): The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer. PubMed 36609396
- Cell Death Dis, 2021 (senior author): miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer. PubMed 34257270
- Oncogene, 2018 (first author): AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. PubMed 29551771
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion